Mesothelioma  >>  Imjudo (tremelimumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imjudo (tremelimumab) / AstraZeneca, Pfizer
NCT02141347: Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Checkmark Presentation of data from MEDI4736 + tremelimumab combo study in Japanese patients with solid tumors (tumor type not specified)
Sep 2015 - Sep 2015: Presentation of data from MEDI4736 + tremelimumab combo study in Japanese patients with solid tumors (tumor type not specified)
Checkmark ECC 2015
Sep 2015 - Sep 2015: ECC 2015
Completed
1
65
Japan
Tremelimumab, MEDI4736
AstraZeneca
Part A and B: Advanced Solid Malignancies, Part C: Malignant Mesothelioma
01/17
01/17

Download Options